Compare Stocks: IOVA, ROIV, BNTX, and UTHR

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$90.24 -5.8%	$99.24	$79.52 ▼ $124.00	$22.99B	1.25	1.09 million shs	479,570 shs
IOVA Iovance Biotherapeutics	$14.38 -1.3%	$9.45	$1.76 ▼ $15.30	$6.57B	0.76	15.76 million shs	1.47 million shs
ROIV Roivant Sciences	$34.55 -0.1%	$36.73	$16.00 ▼ $42.50	$25.01B	1.1	6.37 million shs	402,593 shs
UTHR United Therapeutics	$544.69 -1.0%	$512.67	$409.07 ▼ $609.35	$23.37B	0.49	552,402 shs	29,635 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-1.16%	-1.84%	-0.92%	+6.02%	-6.09%
IOVA Iovance Biotherapeutics	-0.41%	+2.90%	+69.30%	+270.48%	+593.33%
ROIV Roivant Sciences	-2.40%	-3.33%	-15.26%	-0.92%	+115.65%
UTHR United Therapeutics	+0.17%	+2.55%	+10.66%	+4.45%	+25.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$90.24 -5.8%	$99.24	$79.52 ▼ $124.00	$22.99B	1.25	1.09 million shs	479,570 shs
IOVA Iovance Biotherapeutics	$14.38 -1.3%	$9.45	$1.76 ▼ $15.30	$6.57B	0.76	15.76 million shs	1.47 million shs
ROIV Roivant Sciences	$34.55 -0.1%	$36.73	$16.00 ▼ $42.50	$25.01B	1.1	6.37 million shs	402,593 shs
UTHR United Therapeutics	$544.69 -1.0%	$512.67	$409.07 ▼ $609.35	$23.37B	0.49	552,402 shs	29,635 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	-1.16%	-1.84%	-0.92%	+6.02%	-6.09%
IOVA Iovance Biotherapeutics	-0.41%	+2.90%	+69.30%	+270.48%	+593.33%
ROIV Roivant Sciences	-2.40%	-3.33%	-15.26%	-0.92%	+115.65%
UTHR United Therapeutics	+0.17%	+2.55%	+10.66%	+4.45%	+25.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.65	Moderate Buy	$125.69	36.05% Upside
IOVA Iovance Biotherapeutics	2.62	Moderate Buy	$13.20	-8.49% Downside
ROIV Roivant Sciences	2.79	Moderate Buy	$45.64	32.34% Upside
UTHR United Therapeutics	2.71	Moderate Buy	$627.31	13.54% Upside

Current Analyst Ratings Breakdown

Latest IOVA, ROIV, BNTX, and UTHR Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/13/2026	IOVA Iovance Biotherapeutics	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$18.00
10/12/2026	ROIV Roivant Sciences	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
10/12/2026	ROIV Roivant Sciences	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Peer Perform
10/8/2026	UTHR United Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$677.00 ➝ $708.00
10/8/2026	BNTX BioNTech	Argus Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Hold
10/8/2026	IOVA Iovance Biotherapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Neutral	$6.00 ➝ $11.00
10/7/2026	BNTX BioNTech	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$115.00 ➝ $114.00
10/7/2026	UTHR United Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$515.00 ➝ $566.00
10/2/2026	BNTX BioNTech	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
10/1/2026	UTHR United Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
9/30/2026	IOVA Iovance Biotherapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$14.00 ➝ $18.00

(Data available from 10/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.20	$1.27 per share	72.62	$96.59 per share	0.96
IOVA Iovance Biotherapeutics	$263.50M	24.80	N/A	N/A	$1.76 per share	8.20
ROIV Roivant Sciences	$7.53M	3,307.03	N/A	N/A	$7.35 per share	4.69
UTHR United Therapeutics	$3.18B	7.45	$33.18 per share	16.65	$164.81 per share	3.35

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
IOVA Iovance Biotherapeutics	-$390.98M	-$0.73	N/A	N/A	N/A	-89.11%	-40.51%	-31.65%	11/5/2026 (Estimated)
ROIV Roivant Sciences	-$299.77M	-$0.53	N/A	N/A	N/A	-3,534.96%	-22.94%	-21.53%	11/9/2026 (Estimated)
UTHR United Therapeutics	$1.33B	$27.95	19.77	18.22	2.73	41.56%	20.18%	17.98%	11/4/2026 (Estimated)

Latest IOVA, ROIV, BNTX, and UTHR Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/9/2026	Q2 2027	ROIV Roivant Sciences	-$0.41	N/A	N/A	N/A	$3.74 million	N/A
11/5/2026	Q3 2026	IOVA Iovance Biotherapeutics	-$0.0847	N/A	N/A	N/A	$114.44 million	N/A
11/4/2026	Q3 2026	UTHR United Therapeutics	$6.21	N/A	N/A	N/A	$784.57 million	N/A
11/3/2026	Q3 2026	BNTX BioNTech	$0.8940	N/A	N/A	N/A	$1.20 billion	N/A
8/7/2026	Q1 2027	ROIV Roivant Sciences	-$0.2996	-$0.26	+$0.0396	-$0.26	$2.06 million	$1.44 million
8/6/2026	Q2 2026	IOVA Iovance Biotherapeutics	-$0.1335	-$0.11	+$0.0235	-$0.11	$87.83 million	$99.31 million
8/5/2026	Q2 2026	UTHR United Therapeutics	$6.86	$7.27	+$0.41	$7.27	$804.65 million	$783.30 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
IOVA Iovance Biotherapeutics	N/A	N/A	N/A	N/A	N/A
ROIV Roivant Sciences	N/A	N/A	N/A	N/A	N/A
UTHR United Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
IOVA Iovance Biotherapeutics	N/A	4.34	3.82
ROIV Roivant Sciences	N/A	16.72	16.72
UTHR United Therapeutics	N/A	5.73	5.41

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
IOVA Iovance Biotherapeutics	77.03%
ROIV Roivant Sciences	64.76%
UTHR United Therapeutics	94.08%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
IOVA Iovance Biotherapeutics	7.80%
ROIV Roivant Sciences	8.80%
UTHR United Therapeutics	8.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
IOVA Iovance Biotherapeutics	975	452.97 million	417.64 million	Optionable
ROIV Roivant Sciences	721	722.32 million	658.76 million	Optionable
UTHR United Therapeutics	1,400	42.89 million	39.20 million	Optionable

IOVA, ROIV, BNTX, and UTHR Headlines

Recent News About These Companies

United Therapeutics Presents New Data at the CHEST 2026 Annual Meeting

25 minutes ago | marketscreener.comM

Morgan Stanley Releases a Hold Rating on United Therapeutics (UTHR)

October 11 at 3:19 PM | theglobeandmail.com

United Therapeutics (NASDAQ:UTHR) CEO Sells $5,215,025.00 in Stock

October 11 at 9:00 AM | defenseworld.netD

United Therapeutics Corporation (UTHR) - What Are Investment Firms Thinking About This Stock?

October 11 at 2:28 AM | americanbankingnews.com

United Therapeutics Corporation (NASDAQ:UTHR) Stock Has Average Target Price of $627.31

October 11 at 2:28 AM | marketbeat.com

Why Investors Need to Take Advantage of These 2 Medical Stocks Now

October 9, 2026 | zacks.com

United Therapeutics Corporation $UTHR Shares Newly Purchased by Vilga Financial Planning LLC

October 9, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Stock Gets Price Target Bump from Morgan Stanley

October 9, 2026 | americanbankingnews.com

Insider Selling: United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Company Stock

October 8, 2026 | marketbeat.com

RBC Capital Remains a Buy on United Therapeutics (UTHR)

October 8, 2026 | theglobeandmail.com

3 Reasons to Avoid UTHR and 1 Stock to Buy Instead

October 7, 2026 | finance.yahoo.com

Morgan Stanley Issues Positive Forecast for United Therapeutics (NASDAQ:UTHR) Stock Price

October 7, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) CEO Sells 9,500 Shares of Company Stock

October 6, 2026 | marketbeat.com

Connect Biopharma (NASDAQ:CNTB) vs. United Therapeutics (NASDAQ:UTHR) Financial Analysis

October 4, 2026 | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) Stock Falls 4.1% After Insider Selling

October 4, 2026 | americanbankingnews.com

Top Medical Stocks To Consider - September 30th

October 3, 2026 | americanbankingnews.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Company Stock

October 3, 2026 | americanbankingnews.com

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX), United Therapeutics (UTHR) and NervGen Pharma (NGEN)

October 3, 2026 | theglobeandmail.com

United Therapeutics (NASDAQ:UTHR) CEO Martine Rothblatt Sells 9,500 Shares of Stock

October 2, 2026 | marketbeat.com

United Therapeutics (NASDAQ:UTHR) Shares Down 4.1% on Insider Selling

October 2, 2026 | marketbeat.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Tango Therapeutics (TNGX), Neurocrine (NBIX) and United Therapeutics (UTHR)

October 2, 2026 | theglobeandmail.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, ROIV, BNTX, and UTHR Company Descriptions

BioNTech NASDAQ:BNTX

$90.24 -5.60 (-5.84%)

As of 10:29 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Iovance Biotherapeutics NASDAQ:IOVA

$14.38 -0.19 (-1.27%)

As of 10:29 AM Eastern

Iovance Biotherapeutics, Inc., a commercial-stage biotechnology company, develops and commercializes cell therapies using autologous tumor infiltrating lymphocyte for the treatment of metastatic melanoma and other solid tumor cancers in the United States. The company offers Amtagvi, a tumor-derived autologous T cell immunotherapy used to treat adult patients with unresectable or metastatic melanoma; and Proleukin, an interleukin-2 product for the treatment of patients with metastatic renal cell carcinoma. It also develops lifileucel in combination with pembrolizumab to treat frontline advanced melanoma patients; LN-145 for the treatment of non-small cell lung cancer (NSCLC) and solid tumor cancers; IOV-4001, which is in Phase 1/2 IOV-GM1-201 clinical trial, for the treatment of NSCLC; and lifileucel for gynecological cancers. The company has collaborations and licensing agreements with WuXi Advanced Therapies, Inc.; National Institutes of Health; the National Cancer Institute; H. Lee Moffitt Cancer Center; The University of Texas M.D. Anderson Cancer Center; Cellectis S.A.; Novartis Pharma AG; and Boehringer Ingelheim Biopharmaceuticals GmbH. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Roivant Sciences NASDAQ:ROIV

$34.55 -0.04 (-0.12%)

As of 10:29 AM Eastern

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It develops VTAMA, a novel topical for the treatment of psoriasis and atopic dermatitis; batoclimab and IMVT-1402, the fully human monoclonal antibodies targeting the neonatal Fc receptor across various IgG-mediated autoimmune indications; and RVT-3101, an anti-TL1A antibody for ulcerative colitis and Crohn's disease. The company was founded in 2014 and is based in London, the United Kingdom.

United Therapeutics NASDAQ:UTHR

$544.68 -5.42 (-0.98%)

As of 10:29 AM Eastern

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for treating high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, the company engages in developing RemoPro and Ralinepag for the treatment of PAH; Aurora-GT, a gene therapy product to rebuild the blood vessels in the lungs; and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was incorporated in 1996 and is headquartered in Silver Spring, Maryland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, ROIV, BNTX, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, ROIV, BNTX, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, ROIV, BNTX, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, ROIV, BNTX, and UTHR Company Descriptions

BioNTech NASDAQ:BNTX

Iovance Biotherapeutics NASDAQ:IOVA

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IOVA, ROIV, BNTX, and UTHR Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IOVA, ROIV, BNTX, and UTHR Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IOVA, ROIV, BNTX, and UTHR Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IOVA, ROIV, BNTX, and UTHR Company Descriptions

BioNTech NASDAQ:BNTX

Iovance Biotherapeutics NASDAQ:IOVA

Roivant Sciences NASDAQ:ROIV

United Therapeutics NASDAQ:UTHR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools